Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 5, 2012, Pages 709-717

  Hacha, Jonathan ^a   Tomlinson, Kate ^b   Maertens, Ludovic ^a   Paulissen, Geneviève ^a   Rocks, Natacha ^a   Foidart, Jean Michel ^a   Noel, Agnès ^a   Palframan, Roger ^b   Gueders, Maud ^a   Cataldo, Didier D ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Immunology Research   (United Kingdom)

Author keywords

Inflammation; Inhalation; Mouse model; Pulmonary disease; Therapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 13 ANTIBODY; METALLOPROTEINASE; SODIUM CHLORIDE; STAT6 PROTEIN; TRANSCRIPTION FACTOR;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL INFILTRATION; CLINICAL PROTOCOL; CONTROLLED STUDY; EOSINOPHILIA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MEDIATOR; MOUSE; NONHUMAN;

ADMINISTRATION, INHALATION; AIRWAY REMODELING; AIRWAY RESISTANCE; ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOCONSTRICTOR AGENTS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-13; LUNG; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METHACHOLINE CHLORIDE; MICE; MICE, INBRED BALB C; NEBULIZERS AND VAPORIZERS; OVALBUMIN; STAT6 TRANSCRIPTION FACTOR;

MUS;

EID: 84868321691     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0031OC     Document Type: Article

References (32)

1. Locksley RM. Asthma and allergic inflammation. Cell 2010;140:777-783.
2. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-3556.
3. Desai D, Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol 2009;158:10-19.
4. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony L, Palomares O, et al. Interleukins, from 1 to 37, and interferon-g: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-721.e701-e770.
5. Byers DE, Holtzman MJ. Alternatively activated macrophages and airway disease. Chest 2011;140:768-774.
6. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-1370.
7. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(h)2 cells. Nat Rev Immunol 2010;10:838-848.
8. Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan XY, Tchistiakova L. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011; 187:561-569.
9. Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002;26:202-208.
10. Yang M, Hogan SP, Henry PJ, Matthaei KI, McKenzie AN, Young IG, Rothenberg ME, Foster PS. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-α chain and STAT-6 independently of IL-5 and eotaxin. Am J Respir Cell Mol Biol 2001;25:522-530.
11. Chan V, Burgess JK, Ratoff JC, O'Connor BJ, Greenough A, Lee TH, Hirst SJ. Extracellular matrix regulates enhanced eotaxin expression in asthmatic airway smooth muscle cells. Am J Respir Crit Care Med 2006;174:379-385.
12. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev 2004;202:175-190.
13. Blease K. Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 2008; 9:1180-1184.
14. Kasaian MT, Miller DK. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008;76:147-155.
15. Antoniu SA. Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs 2009;23:241-251.
16. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, Umetsu DT. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167:4668-4675.
17. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004;28:224-232.
18. Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, Rafferty P, Lakshminarayanan M, Griswold DE, Bugelski PJ, et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther 2005;313:8-15.
19. Corren J. Cytokine inhibition in severe asthma: current knowledge and future directions. Curr Opin Pulm Med 2011;17:29-33.
20. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098.
21. Berry LM, Adams R, Airey M, Bracher MG, Bourne T, Carrington B, Cross AS, Davies GC, Finney HM, Foulkes R, et al. In vitro and in vivo characterisation of anti-murine IL-13 antibodies recognising distinct functional epitopes. Int Immunopharmacol 2009;9:201-206.
22. Gueders MM, Hirst SJ, Quesada-Calvo F, Paulissen G, Hacha J, Gilles C, Gosset P, Louis R, Foidart JM, Lopez-Otin C, et al. Matrix metalloproteinase-19 deficiency promotes tenascin-c accumulation and allergen-induced airway inflammation. Am J Respir Cell Mol Biol 2010;43:286-295.
23. Gueders MM, Bertholet P, Perin F, Rocks N, Maree R, Botta V, Louis R, Foidart JM, Noel A, Evrard B, et al. A novel formulation of inhaled doxycycline reduces allergen-induced inflammation, hyperresponsiveness and remodeling by matrix metalloproteinases and cytokines modulation in a mouse model of asthma. Biochem Pharmacol 2008;75:514-526.
24. Paulissen G, Rocks N, Gueders MM, Bedoret D, Crahay C, Quesada-Calvo F, Hacha J, Bekaert S, Desmet C, Foidart JM, et al. ADAM-8, a metalloproteinase, drives acute allergen-induced airway inflammation. Eur J Immunol 2011;41:380-391.
25. Kumar RK, Herbert C,Webb DC, Li L, Foster PS. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 2004;170:1043-1048.
26. Tomlinson KL, Davies GC, Sutton DJ, Palframan RT. Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite. PLoS ONE 2010;5:e13136.
27. Martin PL, Fisher D, Glass W, O'Neil K, Das A, Martin EC, Li L. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma. Int J Toxicol 2008;27:351-358.
28. Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (cat-354) in subjects with asthma. BMC Pulm Med 2010;10:3.
29. Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, Wilson R, Molfino NA. An open-label, single-dose bioavailability study of the pharmacokinetics of cat-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol 2010;69:645-655.
30. Newcomb DC, Boswell MG, Zhou W, Huckabee MM, Goleniewska K, Sevin CM, Hershey GK, Kolls JK, Peebles RS Jr. Human Th17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17a production. J Allergy Clin Immunol 2011;127:1006-1013.e1001-e1004.
31. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
32. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol 2003;111:227-242.